A team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted a head-to-head ...
14 hours ago
0
1
Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ...
Sep 7, 2025
0
21
The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Apr 23, 2024
0
35
Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue ...
Apr 13, 2024
0
49
Researchers have used heart and lung stem cells infected with the virus that causes COVID-19 to better understand how the disease impacts different organs, paving the way for more targeted treatments.
Jun 13, 2023
0
63
New research in the June 2023 issue of Journal of the National Comprehensive Cancer Network has found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was ...
Jun 12, 2023
0
56
